ALETHIA BIOTHERAPEUTICS
Updated 48 days ago
141, Président-Kennedy ave. Suite SB-5100 Montréal, Québec CANADA H2X 1Y4
Alethia is currently focusing on cancer-associated epithelial-to-mesenchymal transition with its AB-16B5 monoclonal antibody, a clinical stage EMT inhibitor to prevent chemotherapy resistance and metastatic tumour invasion...
Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion...
CORPORATE HIGHLIGHTS Privately-held clinical stage Montreal-based biotechnology company Engaged in the discovery and development of therapeutic mAbs
Also known as: Alethia